236 related articles for article (PubMed ID: 35595416)
21. Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease.
McNeill RP; Barclay ML
Curr Opin Pharmacol; 2020 Dec; 55():41-46. PubMed ID: 33120169
[TBL] [Abstract][Full Text] [Related]
22. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
[TBL] [Abstract][Full Text] [Related]
23. Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives.
Irving PM; Gecse KB
Gastroenterology; 2022 Apr; 162(5):1512-1524. PubMed ID: 35167865
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
[No Abstract] [Full Text] [Related]
25. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
Papamichael K; Cheifetz AS
World J Gastroenterol; 2017 Sep; 23(34):6197-6200. PubMed ID: 28974885
[TBL] [Abstract][Full Text] [Related]
26. Medical Management of Inflammatory Bowel Disease.
Rahman S; Patel RK; Boden E; Tsikitis VL
Surg Clin North Am; 2024 Jun; 104(3):657-671. PubMed ID: 38677828
[TBL] [Abstract][Full Text] [Related]
27. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Nguyen NH; Solitano V; Vuyyuru SK; MacDonald JK; Syversen SW; Jørgensen KK; Crowley E; Ma C; Jairath V; Singh S
Gastroenterology; 2022 Oct; 163(4):937-949.e2. PubMed ID: 35753383
[TBL] [Abstract][Full Text] [Related]
28. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?
Anjie SI; Hulshoff MS; D'Haens G
Expert Opin Biol Ther; 2023 Apr; 23(4):341-351. PubMed ID: 37010030
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia.
Bjørlykke KH; Jahnsen J; Brynskov J; Molander P; Eberhardson M; Davidsdottir LG; Sipponen T; Hjortswang H; Goll GL; Syversen SW; Langholz E; Jørgensen KK; Steenholdt C
Scand J Gastroenterol; 2023 Jan; 58(1):25-33. PubMed ID: 35996928
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab.
Restellini S; Chao CY; Lakatos PL; Aruljothy A; Aziz H; Kherad O; Bitton A; Wild G; Afif W; Bessissow T
Inflamm Bowel Dis; 2018 Jun; 24(7):1531-1538. PubMed ID: 29668893
[TBL] [Abstract][Full Text] [Related]
31. A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy.
Yao J; Jiang X; You JHS
Inflamm Bowel Dis; 2021 Jan; 27(2):275-282. PubMed ID: 32311018
[TBL] [Abstract][Full Text] [Related]
32. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
[TBL] [Abstract][Full Text] [Related]
33. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases.
Bourchany A; Gilletta De Saint-Joseph C; Breton A; Barreau F; Mas E
Curr Opin Pharmacol; 2020 Oct; 54():51-58. PubMed ID: 32947075
[TBL] [Abstract][Full Text] [Related]
34. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic Drug Monitoring Increases Drug Retention of Anti-Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn's Disease.
Gofin Y; Matar M; Shamir R; Assa A
Inflamm Bowel Dis; 2020 Jul; 26(8):1276-1282. PubMed ID: 31634402
[TBL] [Abstract][Full Text] [Related]
36. New Zealand Society of Gastroenterology Guidelines on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
Khan A; Berahmana AB; Day AS; Barclay ML; Schultz M
N Z Med J; 2019 Mar; 132(1491):46-62. PubMed ID: 30845128
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring.
Albader F; Golovics PA; Gonczi L; Bessissow T; Afif W; Lakatos PL
World J Gastroenterol; 2021 Oct; 27(37):6231-6247. PubMed ID: 34712029
[TBL] [Abstract][Full Text] [Related]
38. Infliximab pharmacokinetics monitoring in inflammatory bowel disease.
Svoboda P; Kupka T
Vnitr Lek; 2020; 66(8):34-38. PubMed ID: 33740858
[TBL] [Abstract][Full Text] [Related]
39. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
Samaan MA; Arkir Z; Ahmad T; Irving PM
Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
[TBL] [Abstract][Full Text] [Related]
40. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
Conrad MA; Kelsen JR
Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
